BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Lambda Therapeutics partners with Medidata to streamline clinical trial data management

Medidata, a Dassault Systèmes company, announced that Lambda Therapeutics is implementing Medidata's cloud-based clinical solutions – Rave EDC...

April 20, 2023 | News

Agilis Robotics tests animal trial for GI indication, aims 510(k) clearance by 2025 for improved endoscopic surgery.

The system by Agilis Robotics offers a novel combination of features that set it apart from conventional surgical robotic systems. With a remarkably compac...

April 19, 2023 | News

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer announced that Clev...

April 18, 2023 | News

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | News

Roche's Tecentriq plus Avastin Reduces Cancer Return Risk in Phase III Liver Cancer Study

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the...

April 17, 2023 | News

Zenshine's ZX-7101A Meets Primary Endpoint in Phase 2 Study for Adult Flu Treatment

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 17, 2023 | News

AffaMed Therapeutics Approved for Phase 3 Trial of DEXTENZA® in China for Eye Surgery Inflammation and Pain

In addition, AffaMed is pleased to announce that DEXTENZA has recently been approved in Macau, China for the treatment of ocular itchin...

April 17, 2023 | News

Minghui Pharma's MH004 Cream Succeeds in Phase 2 Trial for Atopic Dermatitis, Global Phase 3 MRCT Cleared by FDA

Study met both primary and all key secondary endpoints Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in...

April 14, 2023 | News

Zenshine's ZX-7101A meets primary endpoint in Phase 2 flu treatment study

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 14, 2023 | News

Bone Biologics Gets Approval for Pilot Clinical Trial with NB1 for Spinal Fusion in Australia.

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committ...

April 13, 2023 | News

Bridge Bio Announces First Patient Dosed in Phase 2a Trial of BBT-877 for Idiopathic Pulmonary Fibrosis Treatment

In the Phase 1 study in 2019, BBT-877, a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as...

April 13, 2023 | News

Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bioph...

April 13, 2023 | News

Genexine's GX-E4 Phase 3 trial shows non-inferiority to Mircera for anemia treatment, presented at WCN2023

Kidneys are responsible for 90% of the EPO produced in our bodies. CKD-induced anemia is caused by the failure to produce EPO (erythropoietin) due to long-...

April 12, 2023 | News

Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.

XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a P...

April 10, 2023 | News

Stay Connected